Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented diagnosis of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).~2. Serum total testosterone \< 300 ng/dL based on 2 consecutive blood samples~Exclusion Criteria:~A subject will not be eligible for study participation if he meets any of the following criteria.~1. History of significant sensitivity or allergy to androgens, castor oil or product excipients.~2. Clinically significant findings in the prestudy examinations.~3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or I-PSS score \> 19 points.~4. Body mass index (BMI) ≥ 38 kg/m2.~5. Clinically significant abnormal laboratory values~6. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).~7. History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.~8. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.~9. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.~10. History of stroke or myocardial infarction within the past 5 years.~11. History of, or current or suspected, prostate or breast cancer.~12. History of diagnosed, severe, untreated, obstructive sleep apnea.~13. History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years.~14. History of long QT syndrome or unexplained sudden death in a first degree relative (parent, sibling, or child).~15. Concurrent treatment with medications which may impact the absorption, distribution, metabolism or excretion of testosterone undecanoate (TU) or place the subject at risk for treatment with testosterone.~16. Subject has a partner who is currently pregnant or planning pregnancy during the course of the clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral testosterone undecanoate, LPCN 1021 (Type: EXPERIMENTAL): Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
- Topical testosterone gel 1.62 % (Type: OTHER): Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28

Based on this trial design, predict the completion outcome and termination type (if applicable).